Sunitinib induced resistance of endothelial cells by up-regulating P-glycoprotein and PI3K/Akt pathway

Rong Zhang¹, Limin Huang²⁺*, Di Pan³, Wen Zhang³, Rong Zhang, Limin Huang contributed equally to this work.

¹Department of mechanics (The State Key Laboratory of Functions and Applications of Medicinal Plants, High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guizhou 550025, China, ²Department of Oncology, People’s Hospital of Guizhou Province, Guizhou 550000, China, ³Department of Pharmacology of Meteria Medica (The Key Laboratory of Optimal Utilization of Natural Medicine Resources) School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guizhou 550025, China

Drug resistance is a crucial obstacle to achieve satisfactory chemotherapeutic effects. Numerous studies have shown that the PI3K/Akt signaling pathway plays a significant role in various processes of cellular events and tumor progression, while few studies have focused on the PI3K/Akt signaling pathway in drug resistance of endothelial cells. The present study aims to explore the relationship of PI3K/Akt signaling and cellular resistance to anticancer drugs in human microvessel endothelial cells (HMEC-1). We established stable sunitinib-resistant human microvessel endothelial cells (HMEC-su) after long-term exposure to sunitinib (a small-molecule tyrosine kinase receptor inhibitor) for 12 months. HMEC-su showed significant alternations of cell morphology and exhibited a 2.32-fold higher IC50 of sunitinib than parental HMEC-1 cells. Expression of P-glycoprotein (P-gp) and breast cancer-resistance protein (ABCG2) which mediates drug efflux, increased significantly in HMEC-su lines compared with HMEC-1 cells by western blots assay. Our study further demonstrates that LY294002 (blocking the PI3K/Akt pathway) enhances the sensibility of HMEC-su to suntinib and inhibits the gene transcription and protein expression of P-gp, ABCG2 in HMEC-su cells. In conclusion, these results indicate that LY294002 could reverse P-gp and ABCG2 mediated-drug resistance to sunitinib in HMEC-su cells by inhibiting PI3K/Akt signaling.

Keywords: Drug resistance. Endothelial cells. P-glycoprotein. Sunitinib. PI3K/Akt pathway.

INTRODUCTION

Drug resistance is a major clinical problem in chemotherapy for cancer treatment. For decades, great efforts have been made to understand the underlying mechanisms which seem to be very complex in the tumor microenvironment. Nowadays, it is known that overexpression of specific trans-membrane proteins, known as ATP-binding cassette (ABC) transporters, plays a determinant role in ATP-dependent efflux of exogenous materials or chemotherapeutics from intracellular compartments (Brayboy et al., 2017). The ABC transporter superfamily contains 7 subfamilies and 48 family members. Over-expression of the ABC transporters in cancer cells has been shown to be responsible for the development of chemo-resistance, such as P-gp (MDR1/ABCB1), ABCG2 (BCRP/MXR/ABCP), and Multidrug Resistance Proteins (MRPs) (De Gooijer et al., 2018; Karthikeyan, Hoti, 2015; Kathawala et al., 2015 ). Over-expression of these ABC transporters in cancer cells with drug resistance has been repeatedly reported clinically. Tumor angiogenesis is essential for tumor growth as these vessels supply oxygen and nutrients to the tumor cells, and also facilitate tumor metastasis via blood stream. As endothelial cells (ECs) play a crucial role in angiogenesis,
our study as well as the previous ones provides evidence that endothelial cells acquire drug resistance in tumor microenvironment (Hida et al., 2018; Huang, Christelle, Coelho-Martins, 2013; Zecchin et al., 2017).

Clinic use of tyrosine kinases inhibitors (TKIs) has been adapted clinically in non-small cell lung cancer (NSCLC) (Chen et al., 2018; Na et al., 2017), breast cancer (Shah et al., 2018; Yazdi et al., 2017), and colon cancer (Zhang et al., 2017; O’Neil et al., 2014). Among these TKIs, sunitinib (Sutent TM) is an oral antiangiogenic drug, which targets c-KIT, platelet-derived growth factor receptors α and β (PDGFR α and β), vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and other kinases (Li et al., 2018). It has been shown that repetitive use of TKIs in clinical treatment, induces drug resistance due to up-regulation of ABC transporters in cancer cells (Fan et al., 2018; Peng et al., 2012; Katayama et al., 2016). There are some small molecules that specifically block ABC transporters. Examples are verapamil (VRP, blocking P-gp function), and fumitremorgin C (FTC, blocking ABCG2 function). They have been shown to recover the sensitivity of cancer cells to chemotherapeutic drugs significantly; however, their clinical use is limited by safety concerns due to their high toxicity and low specificity (Nobili et al., 2006; Breier et al., 2014). Thereby, we need to look for high efficacy novel agents with fewer side effects to overcome drug resistance.

PI3K/Akt signaling pathway regulates cell proliferation, survival, apoptosis, and recently it has been shown to induce drug resistance (Li et al., 2012; Guerrouahen et al., 2014). More interestingly, it has been reported that inhibition of the PI3K/Akt signaling pathway by LY294002, a specific pharmacological inhibitor of PI3K, significantly enhances the cancer cell sensitivity to chemotherapeutic drugs and reverses the ABC transporter proteins-mediated drug resistance (Imai et al., 2012; Liu et al., 2015; Xie et al., 2013). Hence we speculate that the PI3K/Akt signaling pathway could be involved in acquired resistance to TKIs in the endothelial cells.

The aim of the current study was to investigate the role of PI3K/Akt signaling pathway in induction of expression of the ABC transporters in human micro vessel endothelial cells (HMEC-1) after long-term sunitinib treatment. We investigated the overexpression of P-gp gene and protein in the acquisition of resistance to sunitinib and evaluated the efficiency of the use of LY294002 to reverse P-gp-mediate drug resistance by modulating PI3K/Akt pathway in HMEC-1. This study is expected to be helpful in designing novel therapeutic strategies to overcome chemotherapy drug resistance.

**MATERIAL AND METHODS**

**Reagents**

The rabbit monoclonal anti-human P-gp (ab-170904) and ABCG2 (ab-108312) antibodies were purchased from Abcam (Cambridge, United Kingdom). Rabbit antibodies against human Akt (C67E7) and p-Akt (Ser473) were purchased from Cell Signaling Technology, Inc (Danvers, MA, USA). P-gp inhibitor VRP (V106), ABCG2 inhibitor FTC (F9054) and LY294002 (L9908) were from Sigma-Aldrich (St. Louis, MO, USA). Sunitinib (S126061) was from Shanghai Aladdin Bio-Chem Technology Co (Shanghai, RPC).

**In vitro assay**

**Cell culture**

Human microvascular endothelial cell (HMEC-1) lines (C0546, Shanghai Guan Dao Biological Engineering Co, Ltd, Shanghai, China) were cultured in RPMI 1640 medium supplemented with 100 µg/mL streptomycin, 100 units/mL penicillin, and 10% fetal bovine serum (FBS) at 37 °C with 5% CO₂. To induce the sunitinib resistance in the cells, increasing doses of sunitinib (at concentration of 0.01 µM to 8 µM) were added into the culture media during a period of more than 12 months to obtain a stable sunitinib resistant cell lines (HMEC-su). No mutagenic agents were used in establishment of these HMEC-su resistance cell lines. All of the cells were digested with trypsin-EDTA once or twice a week during the whole experiment. Drug resistant cells were maintained in the culture media containing sunitinib at the concentration of 8 µM.
**MTT cell proliferation assay**

MTT assay was performed to evaluate cell viability as previously described (Huang, Christelle, Coelho-Martins 2013; Huang et al., 2014). Cells were seeded in 96-well plates (7x10^3 cells/well) after 24 h of inoculation in a medium with 10% fetal bovine serum concentration. Cells were then treated for 72 h with different concentrations of Sunitinib (5 µM to 20 µM) with unaltered serum concentration or the same concentration of DMSO as control. Then plates were washed for 3 times to remove detached cells before use. After adding 20 µL of MTT reagents at concentration of 5 mg/mL dissolved into 200 µL of phosphate-buffered saline (PBS) per well, plates were incubated at 37 °C for 4 h. Formazan salt crystals were dissolved by dimethylsulfoxide and added into the wells. The absorbance value of each well was determined at 490 nm using a microplate reader (ELX800; GE, USA). Half maximal inhibitory concentration (IC_{50}) was defined as the concentration of drug producing 50% inhibition of cell growth. The resistance index (RI) was calculated as the ratio of IC_{50} values between the resistant and parental cells.

**Blocking effect assay**

We used P-gp inhibitor VRP at 100 µM, ABCG2 inhibitor FTC at 5 µM, or PI3K/Akt blocker LY294002 at 10 µM to treat the cells for 24 h or 48 h, and then the cell viability was assessed by the MTT assay. The reversal fold value (RF) was used to determine their efficiency to reverse the drug resistance. It was obtained by calculating the ratio of IC_{50} of the cells treated by sunitinib (at 5-20µM) alone versus IC_{50} treated by sunitinib (at 5-20µM) plus a given inhibitor. All analyses were performed in triplicates and the data were presented as means ± standard deviation (SD).

**Western blotting**

Western blot assay was performed to detect the protein expression of P-gp and ABCG2 in parental cells, HMEC-1, and resistance cells HMEC-su. The cultured cells in the 6-well plates were washed with PBS twice and protein was extracted using proper amount of lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China). The same amount of protein (30 µg/lane) was added to each lane and separated by 8 or 10% SDS-PAGE gel (Beyotime Institute of Biotechnology) and transferred to polyvinylidine difluoride (PVDF) membranes (EMD Millipore, Bedford, MA, USA). The membranes were blocked by 5% skimmed dry milk in TBS containing 0.2% Tween-20 at room temperature for 1 h, and then incubated overnight at 4°C with 1:1000 diluted anti-human P-gp, ABCG2, and Akt,p-Akt antibodies, or with the antibodies against β-actin (1:10000), Tubulin (1:10000). After washed for three times in TBS/Tween buffer, the membranes were incubated with labelled goat anti-rabbit or goat anti-mouse IgG (1:10,000; Beijing Zhongshan Golden Bridge Biotechnology, Co., Ltd., Beijing) for 1 h at room temperature. The blots were visualized using an enhanced chemiluminescence reagent kit (EMD Millipore). Digital images of the blots were photographed using ChemiDoc XRS+ system and analyzed with Image Lab™ Software, Version 5.2 (BioRad, Hercules, CA, USA).

**Quantitative real time PCR (qRT-PCR)**

After treatment by 100 µM VRP or 5 µM FTC for 48 h, HMEC-1 and HMEC-su cells were harvested and total RNA was extracted using an TransZol Up Plus RNA Kit (ER501, Transgen, Beijing, China), and cDNA was synthesized using an easyScrip One-Step gDNA Removal and cDNA Synthesis SuperMix (AE311, Transgen). The mRNA levels were measured using a TransStart Tip Green aPCR Super Mix (AQ141, Transgen) and a CFX Connect™ Real-Time PCR Detection System (Bio-Rad). The primers were synthesized by Sangon Biotech (Shanghai, China) and are listed in the Supplementary Table I. The same amount of cDNA (1 µg/sample) was added to each tube in the experiment. The mRNA levels were quantified using the 2^{-ΔΔCt} method.

Braz. J. Pharm. Sci. 2022;58: e191102
<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDR1</td>
<td>Forward: 5'-CCCATCATTGCAATAGCAGG-3'</td>
</tr>
<tr>
<td></td>
<td>Reverse: 5'-GTTCAAACCTCGCTCCTGA-3'</td>
</tr>
<tr>
<td>BCRP</td>
<td>Forward: 5'-CAGGTCTGTGGTCAATCACA-3'</td>
</tr>
<tr>
<td></td>
<td>Reverse: 5'-TCCATATCGTGGAATGCTGAAG-3'</td>
</tr>
<tr>
<td>β-actin</td>
<td>Forward: 5'-CCCATCATTGCAATAGCAGG-3'</td>
</tr>
<tr>
<td></td>
<td>Reverse: 5'-GTTCAAACCTCGCTCCTGA-3'</td>
</tr>
</tbody>
</table>

**Data analysis**

All data analysis and group comparisons were performed using student t-test and the one way methods of ANOVA with *Post-hoc* correction using GraphPad Prism 6. For all the results, *p*-values < 0.05 was considered as statistically significant. The data were expressed as means ± standard deviation (SD) or standard error (SE). We usually use ANOVA methods with *Post-hoc* correction to analyze qPCR data and cell proliferation/resistance assay and present SE in the figures. All data presented were obtained from at least three independent experiments.

**RESULTS**

**Establishment of Sunitinib-resistant HMEC-su cell line**

Chronic exposure to Sunitinib in the culture medium over 12 months altered the cell morphology (Figure 1A). The parental cells HMEC-1 were spindle-shaped, uniform in size, and with good transparency. However, there were many morphological changes in sunitinib-treated HMEC-su cells, including the increased number of antennae on the surface of individual cells, irregular shapes, and reduced transparency compared with the parental cells. Morphological changes emerged after 6 months, and became obvious and established at 12 months (Figure 1B). In addition, the growth rate of the sunitinib-treated cells was slower than that of the parental HMEC-1 cells as previously described (Wu *et al.*, 2020).

**FIGURE 1** - Morphological changes induced by sunitinib. (A) Comparison of cellular morphology between parental cells HMEC-1 and sunitinib-resistant cells HMEC-su at 12 months. (B) Morphological changes of HMEC-su cells compared with HMEC-1 cells at indicated time points. ×200, Arrow indicates vacuole. Scale bar: 200 µm.
Sunitinib induced resistance of endothelial cells by up-regulating P-glycoprotein and PI3K/Akt pathway

**Endothelial cells resistances to Sunitinib**

The established Su-resistant HMEC-su cell line was maintained in a culture media with sunitinib at a concentration of 8 µM. MTT assay demonstrated that the IC50 value of HMEC-su cells was significantly elevated compared with the IC50 value of HMEC-1 cells from 2 months to 12 months (Figure 2a). After a maintenance for 12 months, the IC50 of the HMEC-su cells was much higher than that of the HMEC-1 cells (16.910 ± 0.561 µM vs. 7.275 ± 0.306 µM), suggesting that the sensitivity of resistant cells to sunitinib decreased (Table II and Figure 2b).

**TABLE II - Acquired resistance of endothelial cells to sunitinib over 12 months**

<table>
<thead>
<tr>
<th>Agents</th>
<th>HMEC-1 IC50 (µM)</th>
<th>HMEC-su IC50 (µM)</th>
<th>Resistance Index (RI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sunitinib</td>
<td>7.275±0.306</td>
<td>16.910±0.561</td>
<td>2.324**</td>
</tr>
</tbody>
</table>

HMEC-1 or HMEC-su were cultured for 72 hours at 37°C in the presence of increasing concentrations of sunitinib and put to MTT assay for detecting cell proliferation. The Resistance index (RI) was defined as the ratio of IC50 of resistant cells to parental cells. **P < 0.01 compared with HMEC-1 cells. Abbreviations: HMEC-1 (human microvascular endothelial cells), HMEC-su (sunitinib-resistant HMEC-1 cells), IC50 (half-maximal inhibitory concentration).

**FIGURE 2 - Resistance to sunitinib and MDR protein expression in HMEC-1 cells and HMEC-su cells.** (a) IC50 values of HMEC-su at different culture time. (b) Cell proliferation was determined by MTT assay, the inhibitory effects of sunitinib on HMEC-1 and HMEC-su was calculated after exposure to sunitinib at concentration of 5µM to 20 µM for 72 hours. The data shown are the means ± SD of triplicate determinations. **P < 0.01 was considered significant while ***P < 0.001 was highly significant, HMEC-su cells vs. HMEC-1 cells. (c) Elevated expression of P-gp and ABCG2 in HMEC-su cells in comparison with HMEC-1 cells. (d) Relative expression is shown, in which the intensity of bands for P-gp and ABCG2 was divided by corresponding β-actin band. All data were obtained from three independent western blot experiments. **P < 0.01 and *P < 0.05 vs. HMEC-1 cells.
Up-regulation of P-gp and ABCG2 in Sunitinib-resistant endothelial cells HMEC-su.

Our results demonstrated that the protein levels of P-gp and ABCG2 in HMEC-su cells increased approximately 3.61 fold and 1.51 fold, respectively (Figures 2c, d) compared with the parental cells. We also determined the changes of P-gp and ABCG2 mRNA levels by qRT-PCR, and showed the Sunitinib-induced up-regulation of P-gp and ABCG2 in HMEC-su cells (3.28-fold and 1.34-fold, respectively) (Figure S1). However, there was no statistical difference in ABCG2 mRNA level between HMEC-1 and HMEC-su cells. The data indicated that up-regulation of P-gp was in correlation with endothelial cell resistance to sunitinib. Time course study showed that the up-regulation of P-gp and p-Akt protein level could be discerned as early as 6 months after the treatment by sunitinib, and the up-regulation became apparent at 12 month (Figure 3ab).

**FIGURE S1** - The effect of P-gp and ABCG2 inhibitors on P-gp and ABCG2 gene expression. (A) P-gp and (B) ABCG2 mRNA level in HMEC-1 and HMEC-su cells using qRT-PCR, verapamil (VRP) at 100 µM and ABCG2 inhibitors fumitremorgin c (FTC) at 5 µM were used on both cells for 48h, respectively. **P < 0.01 and *P < 0.05 vs. HMEC-1 cells.**
Effect of ABC transporter inhibitors in resistant HMEC-su cells

To assess the effect of functional inhibitors of P-gp and ABCG2, 100 µM VRP and 5 µM FTC were used respectively, to determine the cell sensitivity by MTT assay (Table III). The results showed that blocking P-gp by VRP and ABCG2 by FTC in these cells did not decrease the resistance index of HMEC-su to sunitinib remarkably. Furthermore, qRT-PCR test also indicated
that VRP and FTC slightly decreased the expression of ABCG2; however, no effect on the gene expression of P-gp in HMEC-su (Figure S1). In addition, treatment with either VRP or FTC alone caused few changes in the protein level of ABCG2 compared to the untreated resistant cells (Figure S2). Therefore, ABC transporter inhibitors VRP and FTC failed to restore drug sensitivity in these cells.

**TABLE III** - Effects of P-gp and ABCG2 inhibitors in resistance HMEC-su cells

<table>
<thead>
<tr>
<th>Agents</th>
<th>HMEC-1 IC₅₀ (µM)</th>
<th>HMEC-su IC₅₀ (µM)</th>
<th>RI</th>
<th>RF</th>
</tr>
</thead>
<tbody>
<tr>
<td>sunitinib</td>
<td>7.757±0.130</td>
<td>16.910±0.750</td>
<td>2.324**</td>
<td>1.000</td>
</tr>
<tr>
<td>+VRP (100 µM)</td>
<td>7.181±0.162</td>
<td>15.120±0.947</td>
<td>2.110*</td>
<td>1.104</td>
</tr>
<tr>
<td>+FTC (5 µM)</td>
<td>6.961±0.131</td>
<td>15.595±0.982</td>
<td>2.172*</td>
<td>1.070</td>
</tr>
</tbody>
</table>

MTT assay was used to determine IC₅₀ in the presence or absence of P-gp or ABCG2 inhibitors for 48 h followed by 72 hours of sunitinib treatment. The RI was the ratio of IC₅₀ values between the resistant and parental cell lines. The resistance fold (RF) was calculated as the IC₅₀ of HMEC-su in sunitinib-treatment group to the IC₅₀ of HMEC-su in sunitinib/P-gp inhibitor (VRP: verapamil) or sunitinib/ABCG2 inhibitor (FTC: Fumitremorgin C) group, **P < 0.01, *P< 0.05 vs. HMEC-1 cells.

**FIGURE S2** - Effect of P-gp and ABCG2 inhibitors on P-gp and ABCG2 proteins expression. Expression of P-gp, ABCG2 and p-Akt, Akt protein in HMEC-1 and HMEC-su cells was determined by Western blotting. Cells were treated with verapamil (VRP) at 100 µM and ABCG2 inhibitors fumitremorgin C (FTC) at 5 µM for 48h. All data were collected from three independent experiments, **P < 0.01 and *P < 0.05 vs. HMEC-1 cells, #P < 0.05 vs. HMEC-su cells.

**LY294002 enhances the sensitivity of endothelial cells to sunitinib and decreases protein expression of P-gp and ABCG2 in resistant HMEC-su cells**

The results of western blotting revealed an increased expression of p-Akt protein in HMEC-su cells compared with parental cells HMEC-1 (Figure 3a, b). To further investigate whether the PI3K/Akt signaling is involved in progression of the endothelial cell resistance to sunitinib, we evaluated the effects of LY294002 (which inhibits the PI3K activity), on HMEC-su cells. MTT assay results clearly showed that LY294002 remarkably restored sensitivity of the HMEC-su cells to Sunitinib, the IC50 values decreased from 16.695 ± 0.466 µM to 10.341 ±
Sunitinib induced resistance of endothelial cells by up-regulating P-glycoprotein and PI3K/Akt pathway

Sunitinib induced resistance of endothelial cells by up-regulating P-glycoprotein and PI3K/Akt pathway

Previous studies have shown the tyrosine kinase inhibitor induced drug resistance in tumor cells and endothelial cells in vitro, and the resulting development of drug resistance with antiangiogenic therapy in cancer patients (Yazdi et al., 2017; Anreddy et al., 2014; Jayson et al., 2016; Huang et al., 2014). The emerged resistance

0.664 µM (Table IV). Furthermore, addition of LY294002 significantly decreased the protein expression of p-Akt, P-gp and ABCG2 in HMEC-1 and HMEC-su cell lines (Figure 3c, d), but P-gp and ABCG2 inhibitors did not inhibit expression of the total Akt and p-Akt (Figure S2). Similarly, we also found that LY294002 could suppress the up-regulation of P-gp mRNA level in HMEC-su cells by qRT-PCR assay, as well as ABCG2 mRNA in HMEC-su cells (Figure 4). These results demonstrated that LY294002 can reverse ABC family-mediated drug resistance in endothelial cells to Sunitinib by inhibiting PI3K/Akt signaling.

**TABLE IV -** LY294002 enhances the sensitivity of endothelial cells to sunitinib

<table>
<thead>
<tr>
<th>Agents</th>
<th>IC50 (µM)</th>
<th>RI</th>
<th>RF</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HMEC-1</td>
<td>HMEC-su</td>
<td></td>
</tr>
<tr>
<td>sunitinib</td>
<td>7.275±0.306</td>
<td>16.695±0.460</td>
<td>2.295***</td>
</tr>
<tr>
<td>+LY294002 (10 µM)</td>
<td>6.002±0.851</td>
<td>10.341±0.664</td>
<td>1.723**</td>
</tr>
</tbody>
</table>

The IC50 value of HMEC-1 and HMEC-su cells after LY294002 treatment for 24 h followed by 72 hours of sunitinib exposure were detected by MTT assay, the RI was the ratio of IC50 values between the resistant and parental cell lines. The resistance fold (RF) was calculated as the IC50 of HMEC-su in sunitinib-treatment group to the IC50 of HMEC-su with LY294002 at 10 µM, ***P < 0.001 and **P< 0.01 vs. HMEC-1 cells. ##P < 0.01 and #P< 0.05 vs. HMEC-su cells.

**FIGURE 4 -** LY294002 down-regulates gene level of (A) P-gp and (B) ABCG2 in resistant HMEC-su cells at 10 µM after 24 h treatments. Data reflect means ± SE values of three independent experiments with one-way ANOVA with Post-hoc correction. **P < 0.01 and *P< 0.05 vs. HMEC-1 cells, ##P< 0.01 and #P< 0.05 vs. HMEC-su cells.

**DISCUSSION AND CONCLUSION**

Previous studies have shown the tyrosine kinase inhibitor induced drug resistance in tumor cells and
reduces their clinical efficacy. In the present study, we first showed the emerging drug resistance in endothelial cells after long-term exposure to Sunitinib in vitro. We found that the cell morphology of sunitinib-resistant endothelial cells has undergone significant changes, including an increase in the number of antennas on the cell membranes and irregular cell shapes. We demonstrated that the sunitinib-resistant cells HMEC-su exhibited enhanced gene expression of P-gp and ABCG2, and the up-regulation of these protein levels was demonstrated by western blots. These results provided evidence that resistance to sunitinib in these endothelial cells should be closely related to the over-expression of P-gp and ABCG2 molecules which induce efflux of drug from the cells.

The reversibility of resistance to sunitinib in the HMEC-1 cells was investigated in this study as well. Previous reports have shown the effectiveness of ABC transporter inhibitors in inhibiting drug resistance. For example, verapamil inhibited the increased level of drug efflux in FL/Doxo cells and MK571 and verapamil abolished doxorubicin resistance and act as chemosensitizers for DOX therapy in five different NSCLC-derived cell lines (Wu et al., 2017; Liu et al., 2017). We attempted to use the same strategy to suppress sunitinib resistance in HMEC-1 cells but we found that direct inhibition of the ABCG2 by FTC or P-gp by verapamil was not sufficient to reverse the drug resistance of cells to sunitinib. This could be due to the fact that competitive inhibition of the binding sites of the ABC molecules was not sufficient when these molecules were over-expressed, since verapamil and FTC didn’t suppress the over-expression of P-gp and ABCG2 genes in HMEC-su in our study. Our results are consistent with other reports in this regard that inhibitors of ABC transporters including cyclosporin A, verapamil, fumitremorgin C, diethylstilbestrol and MK571 had no effect on multidrug resistance of HMEC-su cells (Huang et al., 2014). In fact, sunitinib and the other TKIs that exhibit substrate-like properties for ABC transporters, also inhibit function of the transporter at lower concentrations by oversaturation of ABC transporters (Anreddy et al., 2014; Elgendy, 2017). Therefore, the inefficiency of ABC transporter blockers in our study has also prompted the search for new agents that could more effectively reverse cancer resistance.

Interestingly, we found that the HMEC-su drug resistant cells exhibited higher PI3K/Akt activity than their parental HMEC-1 cells. This indicated a possible relationship between PI3K/Akt signaling pathway and sunitinib resistance. Therefore LY294002 was used as it blocks the phosphorylation of Akt and PI3K mediated downstream events. More of interest, LY294002 was reported to regulate the cell responses to exogenous substance and anticaner drugs (Xie et al., 2013; Liu et al., 2015; Zhou et al., 2016; Huang et al., 2017; Sui et al., 2014). Our results demonstrated that LY294002 significantly improved the sunitinib sensitivity of HMEC-su cells at 8 µM. We further showed that long-term sunitinib treatment upregulated P-gp 3.61-folds and ABCG2 1.51-folds, however, the addition of LY294002 blocked significantly the gene expressions of P-gp and ABCG2, as well as their protein levels in these HMEC-su cells. As comparison, there was no gene expression change of total Akt in response to LY294002 treatment, showing that this effect was specific for P-gp and ABCG2. Therefore, for the first time, we observed an increase in the chemosensitivity of endothelial cells to sunitinib by blocking the PI3K/Akt pathway, thereby inhibiting the expression of P-gp and ABCG2. These results indicate an alternative way to develop a sensitizer as a new auxiliary agent for sunitinib treatment. Since PI3K/Akt signaling pathway affects cells broadly, the underlying mechanisms that are relevant to the results described above still needs to be explored in further detail. Nevertheless, our findings are encouraging because there is no suitable drug available to reverse the acquired drug resistance to TKIs in clinic. We believe that an understanding of these mechanisms shall be helpful in conceiving the new pharmaceutical strategies and overcoming the resistance to sunitinib and other TKIs in clinic.

ACKNOWLEDGEMENT

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Sunitinib induced resistance of endothelial cells by up-regulating P-glycoprotein and PI3K/Akt pathway

REFERENCES


Received for publication on 10th July 2020
Accepted for publication on 17th October 2020